Autolus Therapeutics plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AUTL research report →
Companywww.autolus.com
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development.
- CEO
- Christian Martin Itin
- IPO
- 2018
- Employees
- 647
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $433.81M
- P/E
- -1.50
- P/S
- 4.69
- P/B
- 3.99
- EV/EBITDA
- -1.54
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -11.19%
- Op Margin
- -285.90%
- Net Margin
- -311.95%
- ROE
- -128.53%
- ROIC
- -56.74%
Growth & Income
- Revenue
- $75.56M · 646.68%
- Net Income
- $-288,199,915 · -30.61%
- EPS
- $-1.08 · -24.14%
- Op Income
- $-281,437,148
- FCF YoY
- -25.81%
Performance & Tape
- 52W High
- $2.70
- 52W Low
- $1.18
- 50D MA
- $1.49
- 200D MA
- $1.56
- Beta
- 1.93
- Avg Volume
- 1.71M
Get TickerSpark's AI analysis on AUTL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Richardson Ryan | other | 80,000 |
| Mar 18, 26 | Piccina Cintia | other | 500,000 |
| Mar 18, 26 | Piccina Cintia | other | 148,000 |
| Mar 18, 26 | Piccina Cintia | other | 33,000 |
| Mar 18, 26 | BUTITTA CYNTHIA M | other | 10,000 |
| Mar 18, 26 | BUTITTA CYNTHIA M | other | 47,095 |
| Mar 18, 26 | BUTITTA CYNTHIA M | other | 25,000 |
| Mar 18, 26 | BUTITTA CYNTHIA M | other | 12,500 |
| Mar 18, 26 | BUTITTA CYNTHIA M | other | 12,500 |
| Mar 18, 26 | BUTITTA CYNTHIA M | other | 20,000 |
Our AUTL Coverage
We haven't published any research on AUTL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AUTL Report →